Real-world data on the clinical use of secukinumab in pediatric generalized pustular psoriasis: A 48-week retrospective study

To the Editor: Generalized pustular psoriasis (GPP) is a rare but often aggressive disease in children. 1 Sachdeva M. Rankin B.D. Mufti A. et al. Management of pediatric generalized pustular psoriasis using biologics: an evidence-based review. Preprint. Posted online October 22, 2021. J Am Acad Dermatol. 2021; https://doi.org/10.1016/j.jaad.2021.10.028 Abstract Full Text Full Text PDF Scopus (6) Google Scholar Currently, there is still a lack of effective treatments for pediatric patients with GPP. 2 Hoegler K.M. John A.M. Handler M.Z. Schwartz R.A. Generalized pustular psoriasis: a review and update on treatment. J Eur Acad Dermatol Venereol. 2018; 32: 1645-1651 Crossref PubMed Scopus (106) Google Scholar Secukinumab, an interleukin 17 inhibitor, has been shown to be effective in the treatment of adult patients with GPP. 3 Imafuku S. Honma M. Okubo Y. et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52-week analysis from phase III open-label multicenter Japanese study. J Dermatol. 2016; 43: 1011-1017 Crossref PubMed Scopus (136) Google Scholar ,4 Miyachi H. Konishi T. Kumazawa R. et al. Treatments and outcomes of generalized pustular psoriasis: a cohort of 1516 patients in a nationwide inpatient database in Japan. J Am Acad Dermatol. 2021; 86: 1266-1274 PubMed Google Scholar However, the long-term efficacy and safety of secukinumab in the pediatric population with GPP remain unknown. Our study aimed to fill this gap in real-world scenarios.